Our Research
2025
Cardiovascular Degeneration in Erdheim-Chester Disease: Prevalence, Burden, and Outcomes. Blood Adv bloodadvances.2025016608.
Current Perspectives on Mesenchymal Dendritic Cell Neoplasms of Lymphoid Tissue: Insights into Ontogeny, Updates on Classification, and Clinicopathologic Characteristics. Cancers (Basel). 2025 Jun 19;17(12):2055.
Cluster analysis reveals the clinical spectrum of Erdheim-Chester disease. Leukemia. 2025 May 28.
Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder. J Clin Endocrinol Metab. 2025 May 19;110(6):1756-1766.
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease. Blood. 2025 May 1;145(18):2100-2103.
Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. Leukemia. 2025 Apr;39(4):991-994.
Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features. Blood Adv. 2025 Mar 25;9(6):1376-1386.
Novel Diagnosis of Isolated Cardiac Erdheim-Chester Disease by Interatrial Biopsy Using Frozen Section Examination. Interv Cardiol. 2025 Mar 17;20:e09.
Modulation of microRNA-502-3p significantly influences synaptic activity, dendritic spine density and mitochondrial morphology in the mice brain. bioRxiv [Preprint]. 2025 Mar 10:2025.03.09.642262.
Rosai-Dorfman disease disguised as BRAF V600E-positive histiocytosis – a diagnostic pitfall. Blood Res. 2025 Feb 28;60(1):13.
Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free? Br J Haematol. 2025 Feb;206(2):792-794.
Erdheim-Chester Disease With Significant Response of Large Vessel Disease to Cobimetinib Monotherapy. Am J Hematol. 2025 Jan 22.
Central nervous system crystal-storing histiocytosis: A case report and literature review. Eur J Neurol. 2025 Jan;32(1):e16528.
2024
Hypofractionated Radiation Therapy for Subcutaneous Rosai-Dorfman Disease: A Case Report. Adv Radiat Oncol. 2024 Dec 30;10(3):101710.
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. JCO Precis Oncol. 2024 Nov;8:e2400471.
SLC29A3 Pathogenic Variants Resulting in Dural Based Fibroinflammatory Mass Lesions and H Syndrome Treated With Cobimetinib: A Case Report. Neurol Genet. 2024 Oct 14;10(6):e200197.
Liver involvement with Langerhans cell histiocytosis in adults. Oncologist. 2024 Oct 3;29(10):e1347-e1353.
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms. Blood Cancer J. 2024 Sep 5;14(1):153.
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15;130(14):2416-2439.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. Br J Haematol. 2024 Jul;205(1):127-137.
Clinical features and outcomes in primary nervous system histiocytic neoplasms. Blood Cancer J. 2024 Jun 20;14(1):101.
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol. 2024 May;99(5):871-879.
Genome-Wide Association Study Identifies the First Germline Genetic Variant Associated With Erdheim-Chester Disease. Arthritis Rheumatol. 2024 Jan;76(1):141-145.
2023
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia. 2023 Nov;37(11):2297-2300.
Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis. Orphanet J Rare Dis. 2023 Nov 30;18(1):372.
Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv. 2023 Nov 14;7(21):6568-6578.
BRAF testing modalities in histiocytic disorders: Comparative analysis and proposed testing algorithm. Am J Clin Pathol. 2023 Nov 2;160(5):483-489.
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood. 2023 Nov 2;142(18):1570-1575.
Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells. Mod Pathol. 2023 Oct;36(10):100268.
Paging all ENT specialists: Sinus manifestations of Erdheim-Chester disease. Br J Haematol. 2023 Oct;203(2):152-153.
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023 Aug 8;7(15):3984-3992.
Patient-reported fatigue and pain in Erdheim-Chester disease: a registry-based, mixed methods study. Haematologica. 2023 Jun 1;108(6):1685-1690.
Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma. Haematologica. 2023 Jun 1;108(6):1702-1706.
Neurological Manifestations of Histiocytic Disorders. Curr Neurol Neurosci Rep. 2023 Jun;23(6):277-286.
ALK-positive histiocytosis involving the cavernous sinus: A deceptive radiologic mimic of meningioma. Radiol Case Rep. 2023 Apr 17;18(6):2259-2263.
Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis. Leuk Res. 2023 Mar;126:107032.
Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes. Ophthalmology. 2023 Jan;130(1):77-86.
2022
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status. JAMA Oncol. 2022 Dec 1;8(12):1816-1820.
Classical and non-classical phenotypes of Erdheim-Chester disease: Correlating clinical, radiographic and genotypic findings. Br J Haematol. 2022 Nov;199(3):454-457.
Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma. Haematologica. 2022 Sep 1;107(9):2276-2279.
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer J. 2022 Jun 28;12(6):97.
Multimodality imaging of cardiac involvement in Erdheim-Chester disease. Eur Heart J Cardiovasc Imaging. 2022 Jun 21;23(7):e276.
Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer J. 2022 Jun 3;12(6):89.
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 Apr 28;139(17):2601-2621.
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw. 2022 Mar 24;20(6):618-621.
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist. 2022 Mar 4;27(2):144-148.
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. Am J Hematol. 2022 Mar 1;97(3):293-302.
Mimics of Erdheim-Chester disease. Br J Haematol. 2022 Feb;196(4):984-994.
2021
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. Am J Hematol. 2021 Dec 1;96(12):1604-1610.
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol. 2021 May 1;96(5):E146-E150.
Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology. 2021 Mar 16;96(11):e1590-e1592.
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020 Jan 31;105(2):348-357.
CHIPping away at Erdheim-Chester disease. Blood. 2021 Jan 28;137(4):434-436.
Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers. Pancreas. 2021 Jan 1;50(1):e6-e8.
Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e66-e75.
Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. Am J Surg Pathol. 2021 Jan;45(1):35-44.
2020
Efficacy of BRAF-Inhibitor Therapy in BRAF(V600E) -Mutated Adult Langerhans Cell Histiocytosis. Oncologist. 2020 Dec;25(12):1001-1004.
Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease. Leuk Lymphoma. 2020 Nov;61(11):2733-2737.
Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020 Jul;61(7):1592-1600.
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 May 28;135(22):1929-1945.
Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. Br J Dermatol. 2020 Feb;182(2):405-409.
Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica. 2020 Jan 31;105(2):e84-e86.
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2020 Jan;105(1):e5-e8.
2019
Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. Br J Haematol. 2019 Oct;187(2):e51-e54.
The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019 Oct;94(10):2054-2071.
Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):441-446.
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood. 2019 Apr 4;133(14):1607-1610.
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. Br J Haematol. 2019 Apr;185(1):140-142.
Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leuk Lymphoma. 2019 Feb;60(2):553-555.
2018
Arterial involvement in Erdheim-Chester disease: A retrospective cohort study. Medicine (Baltimore). 2018 Dec;97(49):e13452.
Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2018 Nov;183(3):520-524.
Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol. 2018 Aug;182(4):579-581.
Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. Clin Case Rep. 2018 Jun 22;6(8):1637-1638.
18F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. J Nucl Med. 2018 May;59(5):774-779.
Neuroradiologic manifestations of Erdheim-Chester disease. Neurol Clin Pract. 2018 Feb;8(1):15-20.
2017
Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. Blood Cancer J. 2017 Dec 15;7(12):647.
Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncol. 2017 Sep 1;3(9):1253-1256.
2016
Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung. Clin Chest Med. 2016 Sep;37(3):421-30.
2015
Erdheim-Chester Disease. Mayo Clin Proc. 2015 Sep;90(9):1310.